ArticleScience advances2022
Host nucleases generate prespacers for primed adaptation in the
Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 20 citations in OpenAlex.
- RecBCD Prevents Bacterial Autoimmunity by Clearing Self-DNA Ends Produced During Replication Termination.bioRxiv : the preprint server for biology · 2026Article
- Article
- SspA is a transcriptional regulator of CRISPR adaptation in E. coli.Nucleic acids research · 2025Article
- A CRISPR-Cas9 system protecting E. coli against acquisition of antibiotic resistance genes.Scientific reports · 2025Article
- DNA polymerase swapping in Caudoviricetes bacteriophages.Virology journal · 2024Article
- Jumping DNA polymerases in bacteriophages.bioRxiv : the preprint server for biology · 2024Article
- RecBCD enzyme: mechanistic insights from mutants of a complex helicase-nuclease.Microbiology and molecular biology reviews : MMBR · 2023Review
- Cas1-Cas2 physically and functionally interacts with DnaK to modulate CRISPR Adaptation.Nucleic acids research · 2023Article
- Genome expansion by a CRISPR trimmer-integrase.Nature · 2023Article
- CRISPR-Cas adaptation in Escherichia coli.Bioscience reports · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
CRISPR-Cas systems provide prokaryotes with adaptive immunity against foreign nucleic acids. In
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.